Rheumatoid Arthritis Clinical Trials in San Francisco, CA

About Rheumatoid Arthritis Clinical Trials in San Francisco

Rheumatoid arthritis (RA) is a chronic autoimmune disease affecting approximately 1.3 million Americans, where the immune system mistakenly attacks joint linings, causing painful swelling, bone erosion, and joint deformity. Early diagnosis and treatment are critical to prevent irreversible damage. Current standard treatments include methotrexate and other DMARDs, TNF inhibitors (etanercept, infliximab), IL-6 inhibitors (tocilizumab), T-cell costimulation modulators (abatacept), and JAK inhibitors (tofacitinib, baricitinib). Clinical trials are now exploring next-generation targeted therapies, dual-pathway inhibitors, and treatment strategies aimed at achieving sustained remission rather than just symptom control. Patients with inadequate response to conventional DMARDs or biologics are commonly eligible for enrollment.

There are currently 81 rheumatoid arthritis clinical trials recruiting participants in San Francisco, CA. These studies are seeking a combined 237,257 participants. Research is being sponsored by TransMedics, American Gastroenterological Association, University of California, San Francisco and 60 other organizations. Clinical trial participation is free and participants receive study-related medical care at no cost.